CTRI/2023/12/060590进行中（未招募）3 期
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
F HoffmannLa Roche Ltd3 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年1月30日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)
研究概览
简要总结
BO42354 is a single arm, multicenter, global Phase III study designed to evaluate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of Crovalimab in patients with aHUS, aged more than 28 days to less than 18 years, and weighing more than 5 kg. Patients will be enrolled in three parallel cohorts, based on their previous exposure and response to complement inhibitor therapy. All cohorts will contribute to PK and safety evaluations of crovalimab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 28.00 Day(s) 至 18.00 Year(s)（—）
- 性别
- All
入选标准
- •Body weight more than 5 kg at screening.
- •Vaccination against Neisseria meningitis serotypes A, C, W, and Y; vaccination against serotype B, according to national vaccination recommendations.
- •Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
- •For participants receiving other therapies (e.g. immunosuppressants, corticosteroids, mTORi, or calcineurin inhibitors: stable dose for more than 28 days prior to screening and up to the first crovalimab administration.
- •For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
- •Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
- •Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
- •Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
- •Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP participants in the Pretreated Cohort only).
- •Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only).
排除标准
- •TMA associated with non-aHUS related renal disease.
- •Positive direct Coombs test.
- •Chronic dialysis and/or end stage renal disease.
- •Identified drug exposure-related TMA.
- •Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease.
- •History of a kidney disease, other than aHUS.
- •History of Neisseria meningitidis infection within 6 months of study enrollment.
- •Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
- •Positive HIV test.
- •Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration.
- •Presence of fever (more than 38 degrees celsius) within 7 days before the first crovalimab administration.
- •Multi-system organ dysfunction or failure.
- •Recent IVIg treatment.
- •Pregnant or breastfeeding or intending to become pregnant.
- •Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
- •Recent use of tranexamic acid.
- •First initiation of plasma exchange/plasma infusions (PE/PI) not more than 28 days prior to first crovalimab administration (for Naive Cohort only).
- •Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
- •Positive for active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor treatment).
- •Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
- •Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to Diacylglycerol kinase ε (DGKE) nephropathy.
结局指标
主要结局
Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)
时间窗: Upto 25 weeks
次要结局
- Naive Cohort Only:(Proportion of patients with platelet count more than LLN at two separate assessments, obtained at least 4 weeks (28 days) apart, by Week 25.)
- Naive and Switch Cohort:(Dialysis requirement status, change from)
- Switch Cohort:(Proportion of patients with maintained TMA)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)Bladder Carcinoma in Situ (CIS)NCT05024773Fidia Farmaceutici s.p.a.130
已完成
3 期
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsChronic Lymphocytic LeukemiaNCT04008706AstraZeneca552
已完成
3 期
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)Biliary Tract CancersNCT05924880AstraZeneca116
已完成
3 期
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesAcromegalyNCT02354508Novartis Pharmaceuticals123
Unknown
3 期
A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and FeverNeutropenia and FeverNCT05108545CSPC ZhongQi Pharmaceutical Technology Co., Ltd.93